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Abstract A 52-year-old man with a medical history of
intravenous drug abuse was admitted to our hospital with
syncope due to torsades de pointes (TdP). Two days
earlier, he had used methadone. The electrocardiogram
showed a prolonged corrected QT interval (QTc) of
600 ms. Continuous telemetry observation showed
multiple episodes of TdP. The patient was diagnosed
with bradyarrhythmia-induced TdP with acquired long
QT syndrome resulting from methadone use. The QTc
normalised within 2 weeks after discontinuation of the
methadone. In this case of a patient with opioid
dependency, there is a reasonable risk of repeated
methadone use. Therefore, implantable cardioverter defi-
brillator or pacemaker implantation is justified but risky
because of possible infections when using intravenous
drugs. Given the high mortality rates seen in untreated
illicit opioid users, this patient needs an alternative
pharmacological treatment. Buprenorphine is an opiate-
receptor agonist associated with less QTc prolongation.
The patient was referred to a rehab clinic and treated
with an oral combination of buprenorphine and naloxone
(Suboxone). During this therapy, his QTc remained
normal.
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Introduction
Long QT syndrome (LQTS) is a disorder of myocardial
repolarisation characterised by a prolonged QT interval on the
electrocardiogram (ECG). This syndrome is associated with an
increased risk of a characteristic life-threatening cardiac
arrhythmia known as torsades de pointes (TdP). The primary
symptoms in patients with LQTS include palpitations, syn-
cope, seizures, and sudden cardiac death (SCD). The LQTS
may be either genetic or acquired.More than ten different types
of congenital LQTS have been identified [1]. Part of the
acquired LQTS is also based on LQT-related gene mutations.
Case
A 52-year-old man with a medical history of intravenous drug
abuse and hepatitis C was admitted to our hospital with TdP.
The patient had collapsed and was found on the ground. Two
days earlier, he had used methadone, intravenous heroine, and
cocaine. The patient had complained of dizziness and syncope
before. There was no family history of SCD. Auscultation of
the heart did not reveal murmurs. Further physical examina-
tion showed no abnormalities besides a haematoma in the
right flank. During examination, TdP were observed on the
monitor (Fig. 1).
Laboratory results showed no hypokalaemia or hypomag-
nesaemia. The electrocardiogram showed a prolonged cor-
rected QT interval (QTc) of 600 ms (Fig. 2). Continuous
telemetry observation showed multiple episodes of TdP.
Metoprolol 50 mg, twice daily, induced mild bradyarrhyth-
mia (50 beats/min) with augmentation of the episodes of
TdP. Isoprenaline was started, after which no more TdP were
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Fig. 1 Torsades de pointes observed on the monitor during examination
Fig. 2 ECG showing a prolonged corrected QT interval
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seen. Angiography of the coronary arteries and the left
ventricle did not show any abnormalities. The patient was
diagnosed with bradyarrhythmia-induced TdP with acquired
LQTS resulting from methadone use. The QTc normalised
within 2 weeks after discontinuation of the methadone
(Fig. 3). The patient was referred to a rehab clinic and
treated with an oral combination of buprenorphine and
naloxone (Suboxone). During this therapy, his QTc remained
normal. Three months later, the patient was still clean. He
refused implantable cardioverter defibrillator (ICD) or
pacemaker implantation because of possible complications
in case of a drug relapse.
Discussion
Some patients with acquired LQTS appear to have a ‘forme
fruste’ of congenital LQTS, in which a mutation or
polymorphism in one of the LQTS genes is clinically silent
until the patient is exposed to a particular drug or other
predisposing factors. QT prolongation is known to be
associated with methadone and is caused by blocking of the
human ether-a-go-go-related gene potassium channels
mimicking the type 2 of the long QT syndrome [2]. In this
case of bradycardia-induced TdP, the initial therapy with β-
blockade was actually contraindicated. The treatment of
choice should be intravenous administration of potassium
and magnesium, even if blood levels are within the normal
range. Magnesium decreases the influx of calcium, thus,
lowering the amplitude of early after-deporlarisations [3, 4].
Raising of extracellular potassium concentration increases the
efflux of potassium ions from myocardial cells, thus, causing
rapid repolarisation [5]. If episodes of TdP persist, then
elevation of the heart rate is indicated, at first instance with
isoprenaline, or in case of an insufficient rise of the heart rate,
by overdrive pacing. In the long term, overdrive pacing can
be performed with a permanent pacemaker or an ICD.
In patients with opioid dependency, there is a reasonable
risk of repeated methadone use. Therefore, ICD or
pacemaker implantation is justified but risky because of
possible infections when using intravenous drugs.
At present, it is not known how often QT prolongation
occurs with methadone use, although it appears to be reported
infrequently. This may be due to under-recognition, particu-
larly in patients being treated for opioid dependence. Sudden
death may be attributed to either narcotic overdose or
complications arising from long-term narcotic abuse [6].
Given the high mortality rates seen in untreated illicit opioid
users and the clear efficacy of methadone in treating opioid
addiction, these patients need an alternative pharmacological
treatment. In patients with risk factors for QT interval
prolongation, buprenorphine has been used. Buprenorphine
is a partial μ-opiate-receptor agonist and a κ-opiate-receptor
antagonist and is associated with less QTc prolongation.
Conclusion
Methadone can induce life-threatening TdP in patients
with a genetic or acquired LQTS. In patients with opioid
Fig. 3 ECG showing a normalised corrected QT interval
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dependency, there is a reasonable risk of repeated
methadone use. Therefore, pacemaker or ICD implanta-
tion to avoid bradycardia-induced TdP is justified, but
risky because of possible infections when using intrave-
nous drugs. Given the high mortality rates seen in
untreated illicit opioid users, these patients need an
alternative pharmacological treatment. Buprenorphine
can be a safe alternative to methadone in opioid-
dependent patients with risk factors for QT interval
prolongation.
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